Conference Coverage

ASH: Novel GBT440 reduces sickle cells, improves hematologic parameters


 

AT ASH 2015

References

Dr. Thompson moderated the briefing in which Dr. Hemmaway presented the data.

The study is supported by Global Blood Therapeutics. Dr. Hemmaway had no relevant disclosures. Several co-investigators are employees of the company. Dr, Thompson had no disclosures relevant to the study.

Pages

Recommended Reading

NHLBI expert panel issues guideline on sickle cell disease
MDedge Family Medicine
Sickle cell anemia trial halted because of early success
MDedge Family Medicine
Stem cells from sickle cell disease patients used to generate gene-corrected cells
MDedge Family Medicine
More than 75% with sickle cell crises don’t get hydroxyurea
MDedge Family Medicine
Hydroxyurea boosts O2 saturations in children with sickle cell disease
MDedge Family Medicine
Eculizumab benefited pregnant women with paroxysmal nocturnal hemoglobinuria
MDedge Family Medicine
Antibiotics to reduce microbiota may improve treatment of sickle-cell disease
MDedge Family Medicine
ASH: Oral drug offers alternative to lifelong transfusions in sickle cell
MDedge Family Medicine
VIDEO: RBCs have extended shelf life, randomized trial shows
MDedge Family Medicine
ASH: HLA-identical sibling transplants “excellent” in eligble SCD patients
MDedge Family Medicine